^
Association details:
| Biomarker: | EGFR A763_Y764insFQEA |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
Excerpt:
Our systematic review and additional internal cases identified 16 case instances with advanced EGFR-A763_Y764insFQEA-mutated lung cancer treated with various EGFR TKIs...Outcomes to all types of EGFR TKIs in this cohort were as follows: ORR 62.5% (95% confidence interval [CI]: 39%–86%), disease control rate 87.5% (95% CI: 74%–100%), median PFS 5.5 months (95% CI: 3.8–14.5 mo) and median OS 22.0 months (95% CI: 16.0–25.0 mo). Radiographic responses and clinical benefit from first-, second-, third-generation, and in-development EGFR exon 20 specific TKIs further dovetail the data and confirm that tumor shrinkage is seen with erlotinib, gefitinib, afatinib, osimertinib, and mobocertinib...
DOI:
10.1016/j.jtocrr.2020.100051
